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Abstract
Purpose The study investigated the feasibility of a posi-
tron-sensitive hand-held detector system for the intraoper-
ative localisation of tumour deposits resulting from
intravenous [
18F]FDG administration.
Methods A total of 17 patients (12 receiving preoperative
[
18F]FDG PET imaging) with various histologically proven
malignancies were included. Radioactivity from tumours
and surrounding normal tissue was measured on average
3 h after administration of 36–110 MBq [
18F]FDG and the
tumour-to-background (T/B) ratio was calculated. In addi-
tion, phantom studies were performed to evaluate the
spatial resolution and sensitivity of the probe.
Results All known targeted tumour sites were identified by
the positron probe. T/B ratios were generally high, with a
mean T/B ratio of 6.6, allowing easy identification of most
tumour sites. In one case of a hepatic metastasis, the T/B
ratio of 1.34 was below expectations, since the preoperative
[
18F]FDG PET scan was positive. The probe was instru-
mental in the localisation of three additional tumour lesions
(two lymph nodes, one anastomotic ring) that were not
immediately apparent at surgery. Phantom studies revealed
that [
18F]FDG-containing gel (simulating tumour tissue),
having 10 times more [
18F]FDG than surrounding “normal”
background gel, was clearly detectable in quantities as low
as 15 mg. As measured in two cases, the absorbed radiation
doses ranged from 2.5 to 8.6 μSv/h for the surgical team to
0.8 μSv/h for the aesthetician.
Conclusion [
18F]FDG-accumulating tumour tissues can be
localised with positron probes intraoperatively with a low
radiation burden to the patient and medical personnel. The
methodology holds promise for further clinical testing.
Keywords Positronprobe. 18F-2-fluoro-2-deoxy-D-
glucose.Tumourimaging.Intraoperativetumour
localisation
Introduction
Surgery can potentially cure locally metastasising solid
tumours. Nevertheless, the presence of residual disease
following conservative surgical treatment is a common
cause of locally recurrent cancer and might also be the
source of distant metastases. Reliable intraoperative identi-
fication of small cancer masses would permit the surgeon to
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Ann Arbor, MI 48109-0028, USAselectively resect malignant tissue. Probe-guided surgery
might allow the identification of tumour lesions that have
remained undetected by preoperative imaging. Also, highly
sensitive probe systems might be useful to differentiate
tumour from scar after neoadjuvant cancer treatment and
might allow the detection of small tumour masses at the
level of resection margins.
Positron emission tomography (PET) with fluorine-18
labelled fluorodeoxyglucose ([
18F]FDG) localises malig-
nant tissue based on the up-regulation of glucose trans-
porters and subsequent phosphorylation by hexokinase.
Although the specificity of [
18F]FDG for malignant tissue is
limited, whole-body [
18F]FDG PET imaging has been
applied with tremendous success in a large number of
malignancies for staging of initial and recurrent disease [1].
Additional oncological applications of PET are rapidly
being developed and there is likely to be further expansion
in applications with the availability of new positron-
emitting radiopharmaceuticals for clinical use [2–4]. There-
fore, intraoperative hand-held probes that detect beta
particles (positrons) emitted from the radioactive decay of
fluorine-18 have recently been developed [5–10]. Selective
detection of beta particles may be advantageous for the
localisation of very small amounts (mg) of tumour tissue.
Beta particles resulting from the decay of fluorine-18 have
a mean range of only 0.5 mm, and a maximum range of
2.4 mm in water before annihilation into two 511-keV
photons [11, 12]. The short range of positrons in tissue
necessitates primary localisation of suspected tumour tissue
either visually by the surgeon or by using a high-energy
gamma detector.
We tested a newly built commercially available beta and
gamma probe system (SI PET-Probe System, Silicon
Instruments, Berlin, Germany) that uses silicon detectors.
The system is capable of simultaneous beta particle and
high-energy photon detection using two separate probes.
Materials and methods
Beta probe
The detector unit of the intraoperative beta-probe system
used in this study consists of a silicon detector incorporated
into a single compact unit. The detector’s design has been
optimised for a high beta particle sensitivity and low
absorption of detector-penetrating photons. The shaft of the
probe has a diameter of 11 mm while the tip of the detector
has an outer diameter of 16 mm with an active circular
detector area of 20 mm
2 at the tip of the probe. The front
face of the tip is covered with an extremely thin layer of
light-impenetrable foil to ensure insensitivity to light and
electromagnetic shielding. Electrical connections from the
detectors to the electronics boards located in the probe
handle are routed through a stainless steel tube connecting
the probe tip and handle. The probe weighs 65 g and is
easily handled by the surgeon (Fig. 1).
High-energy gamma probe
The high-energy gamma probe detector unit is a shielded
silicon detector with a CsI(Tl) scintillation crystal gamma
probe weighting 160 g. As recommended by the manufac-
turer, the energy threshold for 511-keV photon detection
was set to 460 keV, electronically discarding photons with
lower energy. The tip of the detector has an outer diameter
of 11 mm with an active circular detector area of 16 mm
2 at
the tip of the probe. All measurements were done using a
tungsten-shielded high-energy collimator provided with the
system, which narrows the detector window to a diameter
of 8 mm (Fig. 1).
For both probes, the variable-height pulses produced by
the charge amplifiers were transmitted to the power- and
pulse-processing module through 350 cm of shielded,
multi-conductor cable. Sealed, watertight connectors were
used to exclude the potential for electrical shock during use
in surgery. Further technical specifications were not
disclosed by the manufacturer.
Fig. 1 Positron (a) and collimated high-energy gamma (b) probes
manufactured by Silicon Instruments (Berlin, Germany)
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Probe performance for the detection of beta particles and
511-keV gamma rays (photons) was tested using [
18F]FDG
solution.
Sensitivity and linearity measurements
The counting rates of the probe were measured in air as a
function of source strength over 26.3 h at 1-mm distance
from a point source of [
18F]FDG (dried 1-μl drop of [
18F]
FDG solution of less than 500 μm diameter). The amount
of radioactivity ranged from 409 to 0.06 kBq over the
length of the experiment. For annihilation photon detection
testing, the point source was covered with a 1.0-mm-thick
and 20-mm-wide piece of aluminium, sufficiently absorb-
ing all beta particles emitted. Thus, the detector unit was
bombarded with a pure flux of aluminium-penetrating 511-
keV annihilation photons. The beta and photon data were
fitted as a function of radioactivity using linear regression
analysis, obtaining the sensitivity for beta particles and
annihilation photons.
Resolution measurements
Resolution measurements were performed with the positron
probe. The tip of the probe was positioned 1.0 mm above a
dried 185 kBq [
18F]FDG point source. This point source
was then moved in 1.0-mm steps to both sides of the
probe’s tip, which was either covered with a 60 (±4) μm
thick latex foil (Microtek Probe Cover, Bremen, Germany)
or uncovered. The full-width at half-maximum (FWHM)
measurement was calculated from counts relative to 50% of
maximum.
Probe phantom measurements
A simple phantom was used to simulate the detection of
small amounts of superficial tumour tissue within back-
ground activity resulting from normal tissues. Briefly, a 12-
cm-diameter cylindrical plastic container was filled with
5 MBq of [
18F]FDG, 30 g of gelatine and 200 ml of H2O,
stirred and refrigerated for 5 h until a semisolid, flat gel
resulted, simulating normal background tissue. Various
amounts of equally dense gel (15, 25, 75, 250 or
1,000 mg), having a [
18F]FDG concentration 10 times
higher than background, were used to simulate tumour
tissue. Cubic pieces of “tumour” gel were implanted into
the “background” gel, retaining a flat surface. The latex
foil-covered positron and gamma probe heads were
advanced in millimetre steps within 10 mm of the “tumour”
gel’s centre and in 2-mm steps for the remainder of a 2-cm-
wide area around the “tumour” centre (Fig. 2). All
measurements were corrected for physical decay and
performed in triplicate.
PET phantom measurements
A cylindrical phantom containing 9.4 l of water was filled
with 37 MBq of [
18F]FDG as background. Fifteen, 25, 75,
250 or 1,000 μlo f[
18F]FDG solution containing 10 times
more activity than background was filled into five
appropriately sized spheres. A 10-min static 3D acquisition
was started on an ECAT EXACT HR+ PET scanner
(Siemens/CTI, Knoxville, TN, USA). Image data were
reconstructed using ordered subset expectation maximisa-
tion (OSEM, four iterations, 16 subsets). Attenuation
correction was applied using a measured transmission scan.
Image data were corrected for physical decay, random
counts, dead time and scatter. Images were visually
inspected for hot spots, and volumes of interest were
defined in areas of increased activity to calculate the target
to background ratio.
In vivo performance tests
Patients considered surgical candidates underwent in-
formed consent under approved study by the Technical
University of Munich institutional review board. A total of
17 patients with histologically proven malignancies (five
adenocarcinomas of the distal oesophagus and gastro-
oesophageal junction, three gastric adenocarcinomas, one
thyroid cancer, one breast cancer, two malignant melano-
mas, five colorectal cancers) were included. All patients
underwent routine clinical staging including endoscopy
and CT imaging as needed. Four of the five patients with
Fig. 2 Phantom studies using the positron and gamma detector probe
were performed on a “tumour” g e la tt h es u r f a c eo fal a r g e
“background” gel. The probe’s head was covered by 60-μm thin latex
foil as used during surgery (see Fig. 5 for results)
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oesophageal junction received neoadjuvant chemotherapy.
Based on an established protocol at our institution, [
18F]
FDG PET was performed before and 2 weeks after the
start of chemotherapy. According to that protocol, two
patients were considered as non-responders at PET while
the remaining two were classified as partial responders
[13]. Therefore, all four patients underwent emergency
surgery before completion of the chemotherapy protocol.
The patient’s history, PET imaging and probe measure-
ment results are summarised in Table 1. Intraoperative
probe readings were performed on average 3 h after tracer
injection.
[
18F]FDG PET or PET/CT scanning was performed in a
fasted state with glucose levels less than 120 mg/dl within
2 weeks prior to surgery. Due to the fact that some patients
required urgent treatment and PET or PET/CT was not
immediately available, PET scanning could only be
performed in 12 of the 17 patients. Emission images
covering the area from the neck to the pelvis (seven or
eight bed positions, 5–7 min duration each) were acquired
starting 60 min after injection of 300–400 MBq using an
ECAT EXACT HR+ PET scanner (followed by a measured
transmission scan) or on a Biograph Sensation 16 PET/CT
scanner using the CT data for attenuation correction
(Siemens/CTI, Knoxville, TN, USA). Image data, corrected
for dead time, random events, physical decay and scatter
were reconstructed iteratively using attenuation-weighted
OSEM algorithms (eight iterations, four subsets).
Standardised uptake values (SUVs) were calculated from
an oval region of interest (ROI) measuring 1.5 cm
2 which
was placed in the transaxial slice having the maximum
tumour uptake on PET or PET/CT images. A recent study
comparing SUV measurements obtained with these two
scanners showed insignificant differences of the SUV
measurements, indicating that results are largely inter-
changeable if identical OSEM reconstruction parameters
are chosen [14].
All patients underwent surgery including probe-directed
localisation of [
18F]FDG after intravenous injection of 36–
110 MBq [
18F]FDG prior to anaesthesia. The amount of
tracer injected was determined according to the projected
time span between the start of the procedure and the time of
intraoperative measurements. Intravenous fluids were void
of carbohydrates. At surgery, the probe was covered with a
sterile latex foil (same type as was used for in vitro testing).
The operational field was scanned and absolute counts per
second (cps) were determined at the known tumour sites
and normal tissue of the same organ (at least 5 cm away
from macroscopically visible tumour tissue). Counts were
recorded in real time and visualised on the system’s monitor
as cps. In addition, the system provided auditory signals
Table 1 Patient characteristics, positron probe and PET measurements
No. Age
(yr)
Body weight
(kg)
Inj. activity
(MBq)
TD
(min)
T/B
ratio
SUVmean Histology
1 83 69 93.6 153 9.0 6.8 Metastasis of papillary thyroid cancer
2 40 88 47.0 80 3.5 5.3 Gastric adenocarcinoma
3 69 86 65.5 133 4.9 8.3 Adenocarcinoma of the gastro-oesophageal
junction
4 56 70 41.4 365 3.4 6.6 Recurrent rectal cancer
5 43 86 110.6 300 3.2 – Adenocarcinoma of the colon
6 75 70 44.0 140 5.2 – Adenocarcinoma of the colon
7 63 89 73.6 199 1.3 7.2 Liver metastasis of colon cancer
8 76 66 48.5 149 4.1 4.1 Gastric adenocarcinoma
9 48 72 40.7 189 2.6 4.9 Barret’s cancer
10 60 86 41.1 105 5.6 2.8 Ductal breast cancer
11 57 58 36.6 165 10.4 2.3 Adenocarcinoma of the distal oesophagus
12 67 95 52.9 149 17.2 – Adenocarcinoma of the distal oesophagus
13 59 73 36.3 250 3.3 12.8 Malignant melanoma
14 73 86 37.7 19 12.3 5.0 Malignant melanoma
15 65 84 36.6 171 8.4 3.8 Adenocarcinoma of the colon
16 71 62 37.7 255 16.3 – Gastric adenocarcinoma
17 53 85 40.7 239 11.7 – Adenocarcinoma of the gastro-oesophageal
junction
Mean 62.3 77.9 52.0 184.3 6.6 5.8
SD 12.0 11.0 21.7 72.2 4.8 2.8
TD time difference between injection and probe measurements, T/B tumour/background ratio, SUVmean mean standardised uptake value in tumour
obtained from [
18F]FDG PET or PET/CT imaging
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analysis, measurements were obtained in triplicate using a
gate time of 10 s. The time interval between [
18F]FDG
injection and measurement was recorded. The operative
procedure was otherwise conducted as planned. The lesion-
to-background ratio was calculated using the normal tissue
of the respective tumour-involved organ as background. In
two cases, a suspiciously enlarged lymph node was
identified by the surgeon. Probe readings were performed
from the suspicious as well as the non-involved lymph
nodes for comparison. In one additional case, anastomotic
rings were evaluated using the probe. For comparison,
counts were obtained from normal anastomotic rings
(aboral anastomosis).
Radiation dose measurements
Absorbed doses resulting from the decay of [
18F]FDG in
the operation room were measured with a calibrated digital
dosimeter (Isotrak DoseGUARD S10, Braunschweig, Ger-
many) for the most affected surgeon, his first assistant and
the aesthetician during two procedures. The radiation
detectors were worn beneath clothing at the level of the
anterior chest. All patients received a Foley catheter to
reduce urinary activity during the procedure.
Statistics
Linear fitting was performed with Sigma Plot 8.0 (SPSS
Science). Data are presented as mean ± standard deviation
of measurements.
Results
In vitro measurements
The sensitivity of the beta probe for fluorine-18 positron
detection was measured as 0.25 cps per Bq (250 cps per
kBq) at a distance of 1 mm from a point source without
cover (Fig. 3). Positron sensitivity decreased on average by
33% using the intraoperative 60-μm-thick latex cover. The
probe’s sensitivity to penetrating 511-keV photons was
tested by shielding the probe’s tip with a 1-mm-thick lead
cover and found to be negligible (less than 1.5% of total
counts at any count rate up to 1,000 cps) (Fig. 4). At a
distance of 10 mm to the point source, the sensitivity for
positrons decreased by a factor of 5, while the ratio between
true positron detection and background detection from
penetrating photons increased slightly to 3.5% of total
counts.
Linearity was maintained in the clinically important
range (20–1,000 cps) and above to a count rate of
approximately 10,000 cps (equivalent to approx. 50 kBq
at point source). At higher activities (>50 kBq), linearity
was increasingly lost owing to dead time (data not shown).
The sensitivity of the high-energy photon probe for
fluorine-18 was measured to be 0.066 cps per kilobecquerel
at a distance of 1 mm from a point source without any
cover (data not shown). Linearity was maintained through-
out the investigated range of activity up to 500 kBq.
However, the sensitivity of this high-energy photon probe
Fig. 3 Sensitivity testing of the positron probe revealed approximate-
ly 250 counts per second (cps) recovered from a point source of 1 kBq
of [
18F]FDG
Fig. 4 In vitro resolution testing of the positron probe with a fluorine-
18 point source at 1-mm distance from the point source. Use of a 60-
μm thin plastic cover (black circles) decreased sensitivity by roughly
one-third compared with uncovered measurements (black triangles).
Lead shielding (white circles) demonstrates the insensitivity of the
positron probe to penetrating 511-keV photons
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Consequently, intraoperative measurements were only
performed with the beta probe.
At 1 mm distance from point source, the FWHM of the
positron probe was determined to be approximately 5 mm
(Fig. 4). At 10-mm distance from source, the resolution
decreased slightly to an FWHM of approximately 8 mm.
Phantom measurements
Phantom measurements were performed with the beta and
high-energy photon probes covered with latex foil. Without
the presence of background activity, the net decay-corrected
beta counting rate for “tumour” gel was indeed nearly 10
times higher than that for “background” gel (9.6:1 ratio).
Nevertheless, this ratio was not recovered during phantom
measurements. The counting ratio between “tumour” and
“background” gel decreased with the reduction in size of
the “tumour” gel (3.6:1 for 1 g, 2.8:1 for 250 mg, 2.5:1 for
75 mg, 2.0:1 for 25 mg and 1.5:1 for the 15 mg “tumour”
gel). Figure 5 displays these ratios, when the count rate at
the centre of the tumour (normalised to 100%) is divided by
the mean activity measured between 1.6 and 2 cm from the
centre. Even when the probe’s head was covered with the
latex foil, 15 mg of “tumour” gel was clearly localised by
the positron probe given the selected “tumour”-to-“back-
ground” ratio of 10:1.
High-energy photon measurements revealed a much
lower T/B ratio of 1.4:1 for the 1 g “tumour” gel, and 1.3:1
for the 250 mg “tumour” gel, while smaller “tumour” gels
remained undetected. For this reason, in conjunction with its
low sensitivity, the high-energyprobe was not considered for
further intraoperative testing.
PET phantom measurements
On the 10-min static acquisition image of the phantom,
only the 250- and 1,000-μl spheres were visually identified,
while smaller spheres containing 15, 25 and 75 μlo f[
18F]
FDG solution remained undetected. Target to background
ratios were 2.7:1 for the 1,000-mg sphere and 2.1:1 for the
250-mg sphere, indicating significant partial volume
effects.
In vivo measurements
Intraoperative tests have verified the feasibility of positron
detection using this device by detecting all primarily
targeted tumour sites. Known tumour tissue was clearly
detected by the beta probe in 16 of 17 cases. The T/B ratios
of primary targeted tumour lesions varied from 1.34:1 to
17.2:1, resulting in a T/B ratio of 6.6±4.8 (mean±SD) for
the entire patient population. However, one [
18F]FDG PET-
positive liver metastasis of a colorectal cancer having a
tumour-to-background ratio of 1.34 was difficult to localise
duringthe procedurebased on positron probe readingsalone.
Besides these primary targeted tumour sites, several
additional [
18F]FDG-positive foci were identified using the
positron probe during the procedures. In one case, a
resection margin at the gastro-oesophageal anastomosis
(stapler anastomosis) was found to have mildly increased
counts at a small portion of the circumference (T/B ratio
1.3:1). Histology revealed the presence of focal tumour
tissue at the level of the resection margin. Also, an
adenocarcinoma of the distal oesophagus barely visualised
on preoperative [
18F]FDG PET imaging was clearly
identified by intraoperative probe measurements (Table 1,
case 11). Intraoperative positron probe scanning of the
operation field revealed two additional [
18F]FDG-positive
foci (T/B ratio 1.8 and 3.4) in two patients identified by the
surgeon as lymph nodes close to the tumour site (Table 1,
cases 2 and 6). Histological analysis of these lesions
verified the presence of lymph node metastases.
Correlation of imaging and intraoperative beta probe
findings
SUV measurements from PET and PET/CT imaging and
correlative intraoperative probe measurements in relation to
the injected dose and time span between tracer injection and
probe readings are summarised in Table 1. Pre-operative
PET images of patient 11 with a primary distal oesophageal
c a n c e ra r es h o w ni nF i g .6, displaying only mildly
Fig. 5 Simulation of “tumour” tissue detection within background
activity. Detection of variously sized (between 15 and 1,000 mg) high-
activity gel masses (simulatingtumour tissue) within backgroundactivity
having 10 times less activity compared with the target using non-
pressured direct gel contact. As during surgery, measurements were
obtained using a 60-μm thin latex foil cover
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site. Intraoperative measurements obtained from the tumour
surface and normal oesophagus as background revealed a
T/B ratio of 10.4, indicating that PETand probe readings do
not necessarily correlate. Indeed, regression analysis per-
formed from patients for whom PET imaging was available
(n=12) revealed no significant correlation between the T/B
ratio obtained from probe readings and SUV measurements
(r
2=0.15; n.s.).
Radiation dose measurements
Radiation dose measurements were performed during two
procedures (patients 2 and 4). The length of the procedures
ranged between 2 and 6.25 h. Absorbed radiation doses
ranged from 2.5 to 8.6 μSv/h for the most affected surgeon
to 0.8 μSv/h for the aesthetician.
Discussion
Many solid cancers that metastasise to regional lymph
nodes or, in the case of gastrointestinal cancers, even to
distant organs can potentially be cured by surgical resection
[15]. Minimally invasive techniques have been adapted to
surgical oncology, decreasing morbidity and addressing the
quest for optimal function after tumour resection [16–19].
While current preoperative imaging modalities (ultrasound,
X-ray, CT, MRI, PET, etc.) are used with the intention of
determining a patient’s eligibility for surgery, their overall
performance in identifying all potential metastases remains
suboptimal. Nevertheless, PET has evolved as a powerful
tool for the detection of a large number of cancers. A
variety of radiopharmaceuticals have been developed for
PET imaging of cancer, including those related to increased
amino acid transport, DNA synthesis, somatostatin recep-
tors and tumour hypoxia [2, 4, 20–22], but only [
18F]FDG
has as yet been approved for human use by the FDA. The
physical properties of [
18F]FDG make this molecule
especially useful for intraoperative tumour imaging. The
positron (positively charged electron) emitted from the
proton-rich/neutron-deficient isotope travels only a rather
short (mean range in water=0.5 mm [11]) distance in tissue
before interaction with a negatively charged electron and
subsequent annihilation, resulting in the emission of two
511-keV photons, which are used for coincidence imaging
(PET) and for identification with photon-sensitive high-
energy (gamma) probes, giving an approximation to the
location of maximum positron emission [23]. [
18F]FDG
accumulation in tumour tissue is based on high cellular
uptake, glycolytic rate and subsequent trapping, yielding
excellent tumour-to-background ratios frequently greater
than 10:1 [24].
Most current intraoperative probes are designed for the
detection of relatively low-energy photons emitted from
isotopes such as technetium-99m (140 keV) or indium-111
Fig. 6 Transaxial (a) and coro-
nal (b)[
18F]FDG PET images of
patient 11, displaying a rather
low metabolic activity in a distal
oesophageal cancer (mean SUV
2.3). Intraoperative probe read-
ings verified a high tumour-to-
background ratio of 10.4 at the
surface of the oesophageal can-
cer. The presence of viable
tumour tissue at this location
was verified at histology
1540 Eur J Nucl Med Mol Imaging (2007) 34:1534–1544(170 keV/245 keV) and are, therefore, not well suited for
high-energy gamma or positron detection [9]. Existing
gamma probes have been used for the detection of positron
emitters, but their performance remains well below the
expected performance of dedicated positron probes [7].
Recently, two studies reported on the intraoperative use of
gamma probes specifically designed for the detection of
high-energy photons resulting from the decay of [
18F]FDG.
Using a prototype probe in head and neck cancer patients,
Meller et al. found tumour-to-background ratios between
1.2 and 4.9 and a high sensitivity (95%) for the detection of
metastatic lymph nodes [25]. Gulec et al. investigated 32
patients with various malignancies using a different high-
energy gamma probe [26]. All PET-positive lesions were
detected intraoperatively with tumour-to-background ratios
below 3. Injected radiotracer doses were in the range of
250–370 MBq [
18F]FDG in these two studies, and thus
significantly higher than in this study.
A dedicated positron probe composed of a plastic
scintillator and a bismuth germanate (BGO) crystal was
developed by Yamamoto et al. [27]. The FWHM of this
probe was determined as 11 mm at 5-mm distance from
source, while the sensitivity for positrons was rather low
(2.6 cps/kBq measured 5 mm from the detector surface).
Raylman and Wahl developed a detector unit consisting of
a stack of two ion-implanted silicon detectors [28]. The
sensitivity for the positron detection was found to be
approximately 200 cps/kBq, while the resolution (in
FWHM) was not reported [29]. Zervos et al. investigated
a “beta”-sensitive probe manufactured by Crystal (Berlin,
Germany) in five patients. While technical specifications,
sensitivity and resolution characteristics of this probe were
not specifically stated, the measured tumour to background
ratios after [
18F]FDG administration were generally low
(mean 1.6:1) and not different from those measured with a
gamma probe (Neoprobe Corporation, Dublin, OH) using
high energy window settings [30]. Daghighian et al. built a
now commercially available dedicated positron probe
(IntraMedical, Los Angeles, CA, USA) that uses two
detectors, one that predominantly detects positrons and
another that detects only gamma rays, allowing the
subtraction of background gamma activity from “true”
positron counts. They reported a sensitivity of 108 cps/kBq
and a resolution of 10 mm (FWHM) for a source of 5-mm
width [31]. Essner et al. reported successful detection of
remaining tumour tissue in a single case of a melanoma
metastasis in the neck [8], while Frac et al. investigated 5
patients with recurrent melanoma yielding a sensitivity of
89% and a specificity of 100% using this device [32].
Physical testing results obtained with the positron probe
used in this study compare favourably with previously
tested detectors. At 1-mm distance from a point source of
[
18F]FDG, the sensitivity for positrons was found to be
roughly 250 cps/kBq, while the FWHM was calculated as
5 mm using a point source. At 10-mm distance, sensitivity
decreased fivefold and the FWHM was found to be 8 mm,
indicating that performance is best when direct contact of the
probe with the tissue is established. Covering the probe with
a standard intraoperative ultrasound latex foil (as done in this
study) decreases the sensitivity significantly. The penetration
of positrons through the plastic foil is strongly dependent on
the thickness of the material and may therefore vary between
available products. Since the positron probe used in this
study cannot be gas sterilised, this necessitates a moderate
increase in the administered dose for intraoperative use.
Phantom studies performed with the positron probe
covered with a latex foil revealed that T/B ratios suitable
for intraoperative use were achieved with simulated tumour
tissue as small as 15 mg. Data published by Raylman et al.
[33] as well as our own phantom study indicate that tumour
lesions have to be at least one order of magnitude larger to
be detected under clinical scanning conditions using high-
resolution PET scanners. If gas sterilisation were possible,
probe measurements without latex foil would increase the
sensitivity by approximately one-third, suggesting that even
smaller lesions would become detectable. Thus, under
optimal intraoperative measurement conditions only a few
milligrams of superficial tumour tissue would be necessary
for detection.
To our knowledge, this study is the first to utilise a
dedicated positron probe (beta detection only) for intra-
operative detection of tumour tissue in a series of patients.
All primarily targeted tumours had higher counts than
adjacent normal tissue, and all but one had a T/B ratio greater
than 1.5:1, allowing easy in vivo detection of the primarily
targeted tumour tissue. The suboptimal T/B ratio in a single
case of a liver metastasis despite preoperative visualisation by
[
18F]FDG PET scanning may be due to individual changes
of the hepatic glucose metabolism during surgery. It is well
known that general anaesthesia and intraoperative stress can
have profound effects on liver metabolism and ultimately
may alter hepatic [
18F]FDG uptake as well [34, 35]. Also,
since positrons resulting from the decay of fluorine-18 travel
only up to a maximum range of 2.4 mm in tissue, even a thin
layer of non-malignant tissue above the lesion may render it
impossible to detect the malignancy, because the majority of
positrons will originate from the most superficial tissues and
not from the cancer beneath it. Subsequent studies are
needed to investigate this effect by measuring the thickness
of normal tissue above tumour at the site of measurement.
Intraoperative testing revealed that a ratio between target
tissue and background was most suitable for the detection
of tumour tissue. One can identify the level of radioactivity
at the tissue surface based on the measured counts in real
time by moving the probe’s head in the surgical field from
tumour to adjacent normal background tissue of the same
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ability to set a certain threshold as background activity, a
calculated T/B ratio was used instead of raw counts for
further analysis.
The spatial resolution of the probe decreases with the
size of the detector head, while sensitivity increases with
detector size. However, the spatial resolution is almost
irrelevant for the detection of tumour tissue that has at least
the size of the detector head. In such cases, a high
sensitivity is beneficial since it allows minimisation of the
radiation burden to the patient and personnel. However,
spatial resolution would become relevant if very small
tumour masses (a few milligrams) not easily identifiable by
the human eye were to be targeted. Then, a time-consuming
scan of the surgical bed would be needed. Clearly, an
imaging device based on positron detection that could be
placed into the surgical field would be highly desirable.
The goal of this study was to examine the utility of the
probe for identifying known malignancies and not to attempt
tofind tumourlesions not visualised by preoperative imaging.
Nevertheless, during surgery two [
18F]FDG-positive foci
were identified as being enlarged lymph nodes and later
found to be metastatic lymph nodes at histology. In one case,
anastomotic rings were investigated and one ring was found
to be marginally positive based on probe measurements and
later verified to contain tumour tissue at histology.
Intraoperative probe performance is dependent on two
major factors, the metabolism of the administered radio-
pharmaceutical and the technical performance of the probe.
Physiological parameters that influence the ability to detect
tumour tissue in situ will include the time interval between
tracer injection and scanning, the uptake of the tracer in
tumour tissue compared with its surrounding normal tissue,
and the clearance of the radiopharmaceutical from blood. In
our experience, a minimum T/B ratio of 1.5 is needed for
the operating surgeon to comfortably identify a significant
difference between tumour and normal surrounding tissues.
Since the uptake ratio between tumour and normal tissue
generally increases with time, it seems advantageous to
inject the radiopharmaceutical prior to the start of the
procedure and to adjust the administered dose accordingly.
Also, [
18F]FDG administration before the start of the
procedure should be preferred because the intraoperative
glucose metabolism may be influenced in unpredictable
ways by the surgical trauma as well as the anaesthetics used.
However, injection of the radiopharmaceutical prior to
the start of surgery requires the use of a probe system that
provides optimal sensitivity for positrons, because other-
wise the administered radioactivity may result in a
significant cumulative radiation dose for the surgical team,
if frequent procedures are performed. The probe system
used in this study showed the highest sensitivity of all
positron probes published so far. As a result, the radiation
burden to the patient and the surgical team can be
substantially reduced compared with that associated with
the use of high-energy gamma probes, while still maintain-
ing a favourable high target-to-background ratio [25, 26].
Injected doses of [
18F]FDG were rather low (range 36–
110 MBq). Dose selections were made according to the
anticipated time difference between injection and presumed
intraoperative probe measurements, which can be trouble-
some in the event of unexpected procedural delays. In this
study, intraoperative measurements of absorbed doses
performed in a rather limited number of procedures were
found to be low and ranged from 3 to 9 μSv/h for the most
affected surgeons to 0.8 μSv/h for the aesthetician. Besides
being dependent on the injected dose of [
18F]FDG,
absorbed doses to personnel were essentially influenced
by the distance from the patient’s body and the duration of
exposure. However, these preliminary data suggest that
even frequent repetition of positron-guided surgical proce-
dures would not exceed established dose limits for the
operating room personnel as long as high-sensitivity probes
are used.
Nevertheless, the in vivo testing of the positron probe
revealed technical limitations that need to be addressed by
the manufacturer. First, the relatively large diameter of the
tip of the positron probe currently prevents its use for
endoscopic procedures. However, a significantly smaller
detector design would result in a loss of sensitivity,
potentially limiting its in vivo usefulness. Also, the manu-
facturer was unable to resolve a technical issue in that in-
tense pressure to the detector surface resulted in false
readings. While this technical flaw could easily be prevented
during procedures by using the probe with non-pressured
direct tissue contact, this defect still limits its intraoperative
applications. Most importantly, the sensitivity of the high-
energy gamma probe provided with the system was much
too low to be clinically applicable with the administered
doses of [
18F]FDG. Still, the application of a high-energy
gamma probe would be beneficial if the tumour tissue
cannot be easily exposed during surgery or the tumour
surface is covered by normal non-malignant tissues.
Conclusion
The study demonstrates the feasibility of localising [
18F]
FDG-avid tumour tissue using a positron probe during
surgery. The high sensitivity of the positron probe allowed
procedures to be performed with a low radiation burden to
the patient and personnel, while the high-energy gamma
probe was not clinically useful owing to its low sensitivity.
Based on phantom studies, the amount of tumour tissue
needed for localisation is at least one order of magnitude
smaller compared with whole-body [
18F]FDG PET and the
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18F]FDG deposits (a few milli-
grams) is possible. In this study we have shown that
positron probes are able to identify primary tumours,
malignant lymph nodes and tumour infiltrates in anasto-
motic rings based on their [
18F]FDG uptake during surgery.
However, intraoperative metabolic changes may severely
influence [
18F]FDG uptake and may decrease the achiev-
able tumour-to-background contrast (as demonstrated for a
liver metastasis), indicating that close intraoperative mon-
itoring of the glucose metabolism and proper timing of
measurements is advisable.
As suggested by results from our phantom studies, the
use of high-sensitivity positron probes may allow for the
detection of remaining tumour tissue in resection beds.
However, the detection of such small tumour lesions would
necessitate a thorough and time-consuming exploration of
the operative site, which in many cases may not be feasible.
Given the short range of positrons in tissue, tumour sites
that are covered with benign tissues may potentially remain
unnoticed by positron detection alone. Combined positron/
high-energy gamma detectors with reasonably high sensi-
tivity may be the best choice to overcome this limitation.
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